Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of “Hold” from Analysts

Caris Life Sciences, Inc. (NASDAQ:CAI) has been given a consensus recommendation of “Hold” by the five analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $30.60.

Several research analysts recently commented on CAI shares. Wall Street Zen raised Caris Life Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research note on Monday, December 29th. The Goldman Sachs Group assumed coverage on shares of Caris Life Sciences in a research report on Wednesday. They set a “buy” rating and a $27.00 target price on the stock. Canaccord Genuity Group lowered their target price on shares of Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, March 13th. Finally, Evercore set a $38.00 price target on shares of Caris Life Sciences in a research note on Monday, January 5th.

Institutional Trading of Caris Life Sciences

Institutional investors have recently bought and sold shares of the stock. PointState Capital LP grew its position in Caris Life Sciences by 73.0% in the fourth quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock valued at $181,271,000 after acquiring an additional 2,834,986 shares during the period. UBS Group AG boosted its stake in shares of Caris Life Sciences by 825.9% in the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock valued at $58,924,000 after purchasing an additional 1,948,107 shares in the last quarter. Balyasny Asset Management L.P. boosted its stake in shares of Caris Life Sciences by 23,902.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,660,280 shares of the company’s stock valued at $44,794,000 after purchasing an additional 1,653,363 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Caris Life Sciences by 185.0% in the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock worth $65,974,000 after purchasing an additional 1,587,176 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. increased its position in shares of Caris Life Sciences by 14.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock worth $248,377,000 after purchasing an additional 1,180,200 shares in the last quarter.

Caris Life Sciences Trading Up 4.9%

CAI stock traded up $0.87 during trading on Wednesday, reaching $18.75. 321,011 shares of the stock were exchanged, compared to its average volume of 2,567,865. Caris Life Sciences has a twelve month low of $16.28 and a twelve month high of $42.50. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35. The firm has a market capitalization of $5.30 billion and a P/E ratio of -104.14. The business’s 50 day simple moving average is $20.56.

Caris Life Sciences (NASDAQ:CAI) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The firm had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. Caris Life Sciences’s revenue was up 125.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.73) EPS.

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.